Share on StockTwits

Investment analysts at Leerink Swann raised their price target on shares of Agios Pharmaceuticals (NASDAQ:AGIO) from $51.00 to $65.00 in a note issued to investors on Monday, AnalystRatingsNetwork.com reports. Leerink Swann’s price objective would indicate a potential upside of 83.20% from the company’s current price.

In other Agios Pharmaceuticals news, SVP Glenn Goddard sold 4,000 shares of the company’s stock on the open market in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $38.08, for a total value of $152,320.00. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Agios Pharmaceuticals (NASDAQ:AGIO) traded up 22.77% on Monday, hitting $43.56. 2,181,724 shares of the company’s stock traded hands. Agios Pharmaceuticals has a one year low of $15.77 and a one year high of $49.79. The stock has a 50-day moving average of $37.31 and a 200-day moving average of $28.1. The company’s market cap is $1.376 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, March 6th. The company reported ($0.40) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.34) by $0.06. The company had revenue of $6.70 million for the quarter, compared to the consensus estimate of $6.19 million. Analysts expect that Agios Pharmaceuticals will post $-1.32 EPS for the current fiscal year.

Several other analysts have also recently commented on the stock. Analysts at JPMorgan Chase & Co. upgraded shares of Agios Pharmaceuticals from a “neutral” rating to an “overweight” rating in a research note on Monday. They now have a $55.00 price target on the stock, up previously from $40.00. Finally, analysts at Zacks downgraded shares of Agios Pharmaceuticals from a “neutral” rating to an “underperform” rating in a research note on Monday, March 10th. They now have a $40.90 price target on the stock. One equities research analyst has rated the stock with a sell rating and three have assigned a buy rating to the company’s stock. Agios Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $49.48.

Agios Pharmaceuticals, Inc is a biopharmaceutical company. The Company is intend to apply its deep understanding of metabolism, coupled with the Company’s ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way cancer and inborn errors of metabolism (NASDAQ:AGIO) are treated.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.